Iceland· IS-EU/1/18/1319/004-006+016-020
Hulio
A adalimumab product containing adalimumabum inn, registered in Iceland by Biosimilar Collaborations Ireland Limited. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Adalimumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB04 (adalimumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Adalimumab · ATC L04AB04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of adalimumab costs, country by country.
Normalised to the WHO defined daily dose (2.9 mg), the median price runs from $0.015 in France to $36.00 in Switzerland — a ×2384 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Adalimumab · price per daily dose (2.9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$36.00
- FR France$0.015
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Adalimumabum INN
- Manufacturer
- Biosimilar Collaborations Ireland Limited
- Country
- Iceland (IS)
- ATC code
- L04AB04
- ATC class
- Adalimumab
- Defined daily dose
- 2.9 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
429 interactions on record for adalimumab.
Graded by severity as the source publishes them — 286 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Adalimumab · interactions on record
429 records
- 286 severe
- 136 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Adalimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAMGEVITAAmgen Europe B.V., Breda
- BelgiumAmgevita 40 mgAmgen Europe
- SpainAMGEVITA 40 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAAmgen Europe B.V.
- SwedenAMGEVITA 40 mg Injektionsvätska, lösning i förfylld injektionspennaAmgen Europe B.V.
- PolandAmgevitaAmgen Europe B.V.
- FinlandCyltezoBoehringer Ingelheim International GmbH
- NorwayAmgevitaAmgen Europe B.V.
- SwitzerlandYuflyma 40 mg, solution injectable en seringue préremplie avec protège-aiguilleIQONE HEALTHCARE SWITZERLAND SA
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Hukyndra, Humira
- Liechtenstein · Amsparity, Hefiya
- Norway · Amgevita, Amsparity
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b14ca81e-ecc2-4045-b0ee-56a9b9acf654 GET /v1/drugs/b14ca81e-ecc2-4045-b0ee-56a9b9acf654?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltum lyfjapenna",
"source": "lyfjastofnun",
"atc_raw": "L04AB04",
"marketed": false,
"strength": "40 mg",
"ma_number": "EU/1/18/1319/004-006+016-020",
"substance": "Adalimumabum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í gigtarlækningum, húðsjúkdómum, meltingarsjúkdómum, gigtarsjúkdómum barna, ónæmisfræði og augnlækningum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43360"
}See everything about adalimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.